AKT1E17K -mutated meningioma cell lines respond to treatment with the AKT inhibitor AZD5363.
Peter JohnNatalie WaldtJosephine LiebichChristoph KesselerStefan SchnabelFrank AngensteinI Erol SandalciogluCordula ScherlachFelix SahmElmar KirchesChristian MawrinPublished in: Neuropathology and applied neurobiology (2021)
Our data suggest that AKT1E17K mutated meningiomas are a promising selective target for AZD5363.